Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) study

Bilgin, Burak; ŞENDUR, MEHMET; Yucel, Sebnem; Celik, Emir; Ozyukseler, Deniz; Ayhan, Murat; Basoglu, Tugba; Ilhan, Aysegul; Akdeniz, Nadiye; Gulmez, Ahmet; DOĞAN, İzzet; AKTAŞ, BURAK; Gurbuz, Mustafa; KOCA, SİNAN; PAYDAŞ, SEMRA; TATLI, ALİ; Cinkir, Havva; Alan, Ozkan; EROL, CİHAN; HIZAL, MUTLU; Kut, Engin; Menevse, Serkan; Sakalar, Teoman; Taskaynatan, Halil; Deniz, Gulhan; Karaagac, Mustafa; Avci, Okan; Sen, Erdem; Karatas, Fatih; AKINCI, MUHAMMED; ŞENER DEDE, DİDEM; Demir, Atakan; DEMİRKAZIK, AHMET; Oksuzoglu, Berna; Kilickap, Sadettin; Yumuk, Fulden; YALÇIN, BÜLENT

doi:10.1007/s00432-020-03501-6

Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) study

Copy For Citation

Bilgin B., ŞENDUR M. A. N., Yucel S., Celik E., Ozyukseler D. T., Ayhan M., ...More

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, vol.147, no.7, pp.2145-2152, 2021 (SCI-Expanded)

Publication Type: Article / Article
Volume: 147 Issue: 7
Publication Date: 2021
Doi Number: 10.1007/s00432-020-03501-6
Journal Name: JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database
Page Numbers: pp.2145-2152
Keywords: Afatinib, Erlotinib, Exon 19 del, Gefitinib, NSCLC
Akdeniz University Affiliated: Yes

Abstract

Background The new second-generation tyrosine kinase inhibitors (TKIs) have superior survival outcome and worse toxicity profile when compared with first-generation TKIs according to the results of clinical trials. However, there are limited studies that investigate the efficacy and safety of the new generation TKIs in real-world patients. Thus, we aimed to compare the efficacy and safety of the afatinib, an irreversible inhibitor of ErbB family receptor, and first-generation TKIs in real-world patients.